Ensysce Biosciences Inc (ENSC)
0.5627
-0.01
(-2.09%)
USD |
NASDAQ |
May 08, 16:00
0.5627
0.00 (0.00%)
After-Hours: 20:00
Ensysce Biosciences Enterprise Value: 3.615M for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | 3.615M |
| May 06, 2024 | 3.551M |
| May 03, 2024 | 3.514M |
| May 02, 2024 | 3.573M |
| May 01, 2024 | 3.859M |
| April 30, 2024 | 3.739M |
| April 29, 2024 | 3.749M |
| April 26, 2024 | 3.684M |
| April 25, 2024 | 3.410M |
| April 24, 2024 | 3.497M |
| April 23, 2024 | 3.495M |
| April 22, 2024 | 3.368M |
| April 19, 2024 | 3.588M |
| April 18, 2024 | 3.655M |
| April 17, 2024 | 4.019M |
| April 16, 2024 | 4.135M |
| April 15, 2024 | 4.383M |
| April 12, 2024 | 4.863M |
| April 11, 2024 | 4.927M |
| April 10, 2024 | 5.136M |
| April 09, 2024 | 5.120M |
| April 08, 2024 | 5.120M |
| April 05, 2024 | 5.303M |
| April 04, 2024 | 5.581M |
| April 03, 2024 | 5.285M |
| Date | Value |
|---|---|
| April 02, 2024 | 5.339M |
| April 01, 2024 | 5.120M |
| March 28, 2024 | 5.194M |
| March 27, 2024 | 5.266M |
| March 26, 2024 | 5.405M |
| March 25, 2024 | 5.255M |
| March 22, 2024 | 5.259M |
| March 21, 2024 | 5.127M |
| March 20, 2024 | 5.303M |
| March 19, 2024 | 5.487M |
| March 18, 2024 | 5.339M |
| March 15, 2024 | 5.219M |
| March 14, 2024 | 4.900M |
| March 13, 2024 | 4.900M |
| March 12, 2024 | 4.775M |
| March 11, 2024 | 5.025M |
| March 08, 2024 | 5.158M |
| March 07, 2024 | 1.876M |
| March 06, 2024 | 1.904M |
| March 05, 2024 | 1.932M |
| March 04, 2024 | 1.748M |
| March 01, 2024 | 2.304M |
| February 29, 2024 | 2.336M |
| February 28, 2024 | 2.284M |
| February 27, 2024 | 2.171M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
0.1847M
Minimum
Sep 28 2023
344.04M
Maximum
Jul 02 2021
27.40M
Average
10.14M
Median
Nov 04 2022
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.560M |
| Palatin Technologies Inc | 24.08M |
| iBio Inc | 16.84M |
| Theriva Biologics Inc | -13.05M |
| Oragenics Inc | 4.426M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.503M |
| Total Expenses (Quarterly) | 3.156M |
| EPS Diluted (Quarterly) | -1.37 |
| Earnings Yield | -941.9% |